• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过在 Pocket 2.0 中实施的口袋和对接搜索相结合,对 SARS-CoV-2 治疗相关蛋白中的可成药性腔进行全面映射。

A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0.

机构信息

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Mangiagalli, 25, I-20133 Milano, Italy.

Dompé Farmaceutici SpA, Via Campo di Pile, I-67100 L'Aquila, Italy.

出版信息

Int J Mol Sci. 2020 Jul 21;21(14):5152. doi: 10.3390/ijms21145152.

DOI:10.3390/ijms21145152
PMID:32708196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7403965/
Abstract

(1) Background: Virtual screening studies on the therapeutically relevant proteins of the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) require a detailed characterization of their druggable binding sites, and, more generally, a convenient pocket mapping represents a key step for structure-based in silico studies; (2) Methods: Along with a careful literature search on SARS-CoV-2 protein targets, the study presents a novel strategy for pocket mapping based on the combination of pocket (as performed by the well-known FPocket tool) and docking searches (as performed by PLANTS or AutoDock/Vina engines); such an approach is implemented by the Pockets 2.0 plug-in for the VEGA ZZ suite of programs; (3) Results: The literature analysis allowed the identification of 16 promising binding cavities within the SARS-CoV-2 proteins and the here proposed approach was able to recognize them showing performances clearly better than those reached by the sole pocket detection; and (4) Conclusions: Even though the presented strategy should require more extended validations, this proved successful in precisely characterizing a set of SARS-CoV-2 druggable binding pockets including both orthosteric and allosteric sites, which are clearly amenable for virtual screening campaigns and drug repurposing studies. All results generated by the study and the Pockets 2.0 plug-in are available for download.

摘要

(1) 背景:对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的治疗相关蛋白进行虚拟筛选研究需要对其可成药结合位点进行详细描述,更一般地说,方便的口袋映射是基于结构的计算研究的关键步骤;(2) 方法:除了对 SARS-CoV-2 蛋白靶标的仔细文献搜索外,本研究还提出了一种基于口袋(由著名的 FPocket 工具执行)和对接搜索(由 PLANTS 或 AutoDock/Vina 引擎执行)相结合的口袋映射新策略;这种方法由 VEGA ZZ 程序套件的 Pockets 2.0 插件实现;(3) 结果:文献分析允许在 SARS-CoV-2 蛋白中鉴定出 16 个有前途的结合腔,并且这里提出的方法能够识别它们,显示出的性能明显优于单独的口袋检测;(4) 结论:尽管所提出的策略需要更多的扩展验证,但它在精确描述一组 SARS-CoV-2 可成药结合口袋方面取得了成功,包括正位和变构位点,这些结合口袋显然适用于虚拟筛选和药物再利用研究。研究和 Pockets 2.0 插件生成的所有结果均可下载。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0e6/7403965/58aa6e8d8941/ijms-21-05152-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0e6/7403965/58aa6e8d8941/ijms-21-05152-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0e6/7403965/58aa6e8d8941/ijms-21-05152-g001.jpg

相似文献

1
A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0.通过在 Pocket 2.0 中实施的口袋和对接搜索相结合,对 SARS-CoV-2 治疗相关蛋白中的可成药性腔进行全面映射。
Int J Mol Sci. 2020 Jul 21;21(14):5152. doi: 10.3390/ijms21145152.
2
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则:冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
3
Putative SARS-CoV-2 M Inhibitors from an In-House Library of Natural and Nature-Inspired Products: A Virtual Screening and Molecular Docking Study.来自天然和类天然产物内部文库的假定 SARS-CoV-2 M 抑制剂:虚拟筛选和分子对接研究。
Molecules. 2020 Aug 17;25(16):3745. doi: 10.3390/molecules25163745.
4
Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity.鉴定出刺突蛋白中有一个可成药结合口袋,揭示了一个关键位点,使现有药物有可能具有对抗新冠病毒感染的能力。
BMC Mol Cell Biol. 2020 Jul 1;21(1):49. doi: 10.1186/s12860-020-00294-x.
5
In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.新型 SARS-CoV-2 病毒主要蛋白酶的批准蛋白酶抑制剂的有效性的计算机评估。
Molecules. 2020 May 29;25(11):2529. doi: 10.3390/molecules25112529.
6
In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.计算机筛选鉴定抗 SARS-CoV-2 感染人类蛋白酶的潜在天然产物抑制剂。
Molecules. 2020 Aug 22;25(17):3822. doi: 10.3390/molecules25173822.
7
Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.通过计算方法鉴定一种重新利用的药物作为人类冠状病毒SARS-CoV-2刺突蛋白的抑制剂。
J Biosci. 2020;45(1). doi: 10.1007/s12038-020-00102-w.
8
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.通过基于对接的虚拟筛选和药代动力学方法,针对负责包膜形成和病毒体组装的蛋白质,鉴定针对 SARS-CoV-2 的潜在抑制剂。
Infect Genet Evol. 2020 Oct;84:104451. doi: 10.1016/j.meegid.2020.104451. Epub 2020 Jul 5.
9
Novel Binding Mechanisms of Fusion Broad Range Anti-Infective Protein Ricin A Chain Mutant-Pokeweed Antiviral Protein 1 (RTAM-PAP1) against SARS-CoV-2 Key Proteins in Silico.新型融合广谱抗感染蛋白蓖麻毒蛋白 A 链突变体-雀麦抗病毒蛋白 1(RTAM-PAP1)与 SARS-CoV-2 关键蛋白的计算机模拟结合机制。
Toxins (Basel). 2020 Sep 17;12(9):602. doi: 10.3390/toxins12090602.
10
In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins.基于计算机的 SARS-CoV-2 主要蛋白酶和刺突蛋白药物再利用。
J Proteome Res. 2020 Nov 6;19(11):4637-4648. doi: 10.1021/acs.jproteome.0c00383. Epub 2020 Sep 21.

引用本文的文献

1
Emerging two-dimensional nanomaterial and its modifications for enhanced antiviral applications: a review.用于增强抗病毒应用的新兴二维纳米材料及其改性:综述
R Soc Open Sci. 2025 Sep 3;12(9):242179. doi: 10.1098/rsos.242179. eCollection 2025 Sep.
2
Computer aided design of inhibitor molecules against Vpr protein from different HIV-1 subtypes.针对不同HIV-1亚型的Vpr蛋白的抑制剂分子的计算机辅助设计
In Silico Pharmacol. 2025 Feb 8;13(1):23. doi: 10.1007/s40203-025-00318-4. eCollection 2025.
3
MEDIATE - Molecular DockIng at homE: Turning collaborative simulations into therapeutic solutions.

本文引用的文献

1
Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2.SARS-CoV-2 中 Nsp15 内切核酸酶 NendoU 的晶体结构。
Protein Sci. 2020 Jul;29(7):1596-1605. doi: 10.1002/pro.3873. Epub 2020 May 2.
2
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.通过计算方法分析严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的治疗靶点并发现潜在药物
Acta Pharm Sin B. 2020 May;10(5):766-788. doi: 10.1016/j.apsb.2020.02.008. Epub 2020 Feb 27.
3
Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy.
MEDIATE - 分子在家对接:将合作模拟转化为治疗方案。
Expert Opin Drug Discov. 2023 Jul-Dec;18(8):821-833. doi: 10.1080/17460441.2023.2221025. Epub 2023 Jul 10.
4
A Computational Pipeline to Identify and Characterize Binding Sites and Interacting Chemotypes in SARS-CoV-2.一种用于识别和表征新型冠状病毒中结合位点及相互作用化学型的计算流程
ACS Omega. 2023 Jun 6;8(24):21871-21884. doi: 10.1021/acsomega.3c01621. eCollection 2023 Jun 20.
5
Progress of the "Molecular Informatics" Section in 2022.2022 年“分子信息学”分会进展情况。
Int J Mol Sci. 2023 May 29;24(11):9442. doi: 10.3390/ijms24119442.
6
Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein.鉴定有前景的可成药结合位点及其靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域的灵活性。
Comput Struct Biotechnol J. 2023;21:2339-2351. doi: 10.1016/j.csbj.2023.03.029. Epub 2023 Mar 18.
7
Exscalate4CoV: Innovative High Performing Computing (HPC) Strategies to Tackle Pandemic Crisis.Exscalate4CoV:创新的高性能计算 (HPC) 策略应对大流行病危机。
Int J Mol Sci. 2022 Sep 30;23(19):11576. doi: 10.3390/ijms231911576.
8
Drug repositioning: A bibliometric analysis.药物重新定位:一项文献计量分析。
Front Pharmacol. 2022 Sep 26;13:974849. doi: 10.3389/fphar.2022.974849. eCollection 2022.
9
Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort.在大规模重新利用的努力中,使用 VERO-E6 细胞进行 SARS-CoV-2 的细胞病变效应筛选。
Sci Data. 2022 Jul 13;9(1):405. doi: 10.1038/s41597-022-01532-x.
10
Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants.描述雷洛昔芬作为一种对抗 SARS-CoV-2 及其变体的潜在药物的特性。
Cell Death Dis. 2022 May 25;13(5):498. doi: 10.1038/s41419-022-04961-z.
SARS-CoV-2 的进化分析:非结构蛋白 6(NSP6)的突变如何影响病毒自噬。
J Infect. 2020 Jul;81(1):e24-e27. doi: 10.1016/j.jinf.2020.03.058. Epub 2020 Apr 10.
4
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.利用人血管紧张素转化酶 2 进入 SARS-CoV-2 的结构和功能基础
Cell. 2020 May 14;181(4):894-904.e9. doi: 10.1016/j.cell.2020.03.045. Epub 2020 Apr 9.
5
Structure of M from SARS-CoV-2 and discovery of its inhibitors.SARS-CoV-2 M 结构与抑制剂的发现
Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.
6
The possible of immunotherapy for COVID-19: A systematic review.免疫疗法治疗 COVID-19 的可能性:系统评价。
Int Immunopharmacol. 2020 Jun;83:106455. doi: 10.1016/j.intimp.2020.106455. Epub 2020 Apr 2.
7
Coronavirus membrane fusion mechanism offers a potential target for antiviral development.冠状病毒膜融合机制为抗病毒药物的开发提供了一个潜在的靶点。
Antiviral Res. 2020 Jun;178:104792. doi: 10.1016/j.antiviral.2020.104792. Epub 2020 Apr 6.
8
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.强效泛冠状病毒融合抑制剂抑制 SARS-CoV-2(前称 2019-nCoV)感染,该抑制剂针对病毒的刺突蛋白,具有很强的介导膜融合能力。
Cell Res. 2020 Apr;30(4):343-355. doi: 10.1038/s41422-020-0305-x. Epub 2020 Mar 30.
9
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.SARS-CoV-2 刺突受体结合域与 ACE2 受体复合物的结构。
Nature. 2020 May;581(7807):215-220. doi: 10.1038/s41586-020-2180-5. Epub 2020 Mar 30.
10
Structural basis of receptor recognition by SARS-CoV-2.SARS-CoV-2 受体识别的结构基础。
Nature. 2020 May;581(7807):221-224. doi: 10.1038/s41586-020-2179-y. Epub 2020 Mar 30.